Brasília – The Brazilian Company of Hemoderivatives and Biotechnology (Hemobrás) is advancing new investments and international partnerships to expand domestic production of blood-derived medicines, amid renewed debate over plasma regulation and the role of the state in the sector. A recent agreement with China’s Tiantan includes technology transfer and aims to increase Brazil’s industrial capacity in hemoderivatives.

Public investments are also reinforcing infrastructure and supply capacity, including BRL 116 million allocated through the Growth Acceleration Program (PAC) to modernize plasma storage and distribution. Despite more than BRL 3 billion invested in recent years and the inauguration of new production facilities, Hemobrás still depends on international partners for key stages of production, raising concerns about efficiency and the pace of achieving full national autonomy.

Source: Futuro da Saúde